JP2013528223A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013528223A5 JP2013528223A5 JP2013514346A JP2013514346A JP2013528223A5 JP 2013528223 A5 JP2013528223 A5 JP 2013528223A5 JP 2013514346 A JP2013514346 A JP 2013514346A JP 2013514346 A JP2013514346 A JP 2013514346A JP 2013528223 A5 JP2013528223 A5 JP 2013528223A5
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- methyl
- methylpyrrolidin
- propoxy
- clomen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 4 - ((S) -2 - ((R) -3- methylpyrrolidin-1-yl) propoxy) phenyl Chemical group 0.000 claims description 65
- 125000000217 alkyl group Chemical group 0.000 claims description 11
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 3
- 125000004208 3-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C([H])C(*)=C1[H] 0.000 claims 19
- 150000001875 compounds Chemical class 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 11
- 239000012453 solvate Substances 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 4
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 125000004404 heteroalkyl group Chemical group 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 claims 1
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims 1
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 claims 1
- MGYRMOBJZIUBQC-JDLBOKMSSA-N 4-methyl-2-[4-[(2s)-2-[(3r)-3-methylpyrrolidin-1-yl]propoxy]phenyl]-3-(4-methylsulfonylphenyl)-2h-chromen-6-ol Chemical compound C([C@H](C)N1C[C@H](C)CC1)OC(C=C1)=CC=C1C1OC2=CC=C(O)C=C2C(C)=C1C1=CC=C(S(C)(=O)=O)C=C1 MGYRMOBJZIUBQC-JDLBOKMSSA-N 0.000 claims 1
- 101150065749 Churc1 gene Proteins 0.000 claims 1
- 102100038239 Protein Churchill Human genes 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 230000001548 androgenic effect Effects 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 125000002393 azetidinyl group Chemical group 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000006185 dispersion Substances 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 1
- 125000004428 fluoroalkoxy group Chemical group 0.000 claims 1
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 1
- 238000010253 intravenous injection Methods 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 239000006210 lotion Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 238000010254 subcutaneous injection Methods 0.000 claims 1
- 239000007929 subcutaneous injection Substances 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 239000011593 sulfur Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Chemical group C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Chemical group 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35353110P | 2010-06-10 | 2010-06-10 | |
| US61/353,531 | 2010-06-10 | ||
| PCT/US2011/039669 WO2011156518A2 (en) | 2010-06-10 | 2011-06-08 | Estrogen receptor modulators and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016149008A Division JP6465840B2 (ja) | 2010-06-10 | 2016-07-28 | エストロゲン受容体モジュレーターおよびその用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013528223A JP2013528223A (ja) | 2013-07-08 |
| JP2013528223A5 true JP2013528223A5 (enExample) | 2015-12-03 |
Family
ID=45098650
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013514346A Pending JP2013528223A (ja) | 2010-06-10 | 2011-06-08 | エストロゲン受容体モジュレーターおよびその用途 |
| JP2016149008A Active JP6465840B2 (ja) | 2010-06-10 | 2016-07-28 | エストロゲン受容体モジュレーターおよびその用途 |
| JP2018153006A Pending JP2018203751A (ja) | 2010-06-10 | 2018-08-15 | エストロゲン受容体モジュレーターおよびその用途 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016149008A Active JP6465840B2 (ja) | 2010-06-10 | 2016-07-28 | エストロゲン受容体モジュレーターおよびその用途 |
| JP2018153006A Pending JP2018203751A (ja) | 2010-06-10 | 2018-08-15 | エストロゲン受容体モジュレーターおよびその用途 |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US8703810B2 (enExample) |
| EP (2) | EP2580210B1 (enExample) |
| JP (3) | JP2013528223A (enExample) |
| KR (1) | KR101698238B1 (enExample) |
| CN (1) | CN102939287B (enExample) |
| AU (1) | AU2011264858B2 (enExample) |
| BR (1) | BR112012031464A2 (enExample) |
| CA (1) | CA2800673A1 (enExample) |
| CY (1) | CY1120450T1 (enExample) |
| DK (1) | DK2580210T5 (enExample) |
| EA (1) | EA022551B1 (enExample) |
| ES (1) | ES2627692T3 (enExample) |
| HR (1) | HRP20170786T1 (enExample) |
| HU (1) | HUE033581T2 (enExample) |
| IL (1) | IL223044B (enExample) |
| LT (1) | LT2580210T (enExample) |
| MX (1) | MX2012014431A (enExample) |
| PH (1) | PH12012502419A1 (enExample) |
| PL (1) | PL2580210T3 (enExample) |
| PT (1) | PT2580210T (enExample) |
| RS (1) | RS56042B1 (enExample) |
| SG (1) | SG185637A1 (enExample) |
| SI (1) | SI2580210T1 (enExample) |
| WO (1) | WO2011156518A2 (enExample) |
| ZA (1) | ZA201208603B (enExample) |
Families Citing this family (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20170786T1 (hr) | 2010-06-10 | 2017-08-11 | Seragon Pharmaceuticals, Inc. | Modulatori estrogenskog receptora i njihove uporabe |
| US8853423B2 (en) | 2010-06-17 | 2014-10-07 | Seragon Pharmaceuticals, Inc. | Indane estrogen receptor modulators and uses thereof |
| WO2013056178A2 (en) | 2011-10-14 | 2013-04-18 | Foundation Medicine, Inc. | Novel estrogen receptor mutations and uses thereof |
| MX357496B (es) | 2011-12-14 | 2018-07-11 | Seragon Pharmaceuticals Inc | Moduladores del receptor de estrógenos fluorados y sus usos. |
| AU2012353660A1 (en) | 2011-12-16 | 2014-06-12 | Olema Pharmaceuticals, Inc. | Novel benzopyran compounds, compositions and uses thereof |
| WO2014203129A1 (en) | 2013-06-19 | 2014-12-24 | Olema Pharmaceuticals, Inc. | Combinations of benzopyran compounds, compositions and uses thereof |
| UA117249C2 (uk) | 2013-06-19 | 2018-07-10 | Серагон Фармасьютікалз, Інк. | Модулятор рецептора естрогену та його застосування |
| WO2014203132A1 (en) | 2013-06-19 | 2014-12-24 | Olema Pharmaceuticals, Inc. | Substituted benzopyran compounds, compositions and uses thereof |
| CA2915534A1 (en) | 2013-06-19 | 2014-12-24 | Seragon Pharmaceuticals, Inc. | Azetidine estrogen receptor modulators and uses thereof |
| RU2016137150A (ru) | 2014-03-13 | 2018-04-18 | Ф. Хоффманн-Ля Рош Аг | Способы и композиции для модулирования мутантов эстрогеновых рецепторов |
| CN106572990A (zh) | 2014-03-13 | 2017-04-19 | 豪夫迈·罗氏有限公司 | 含有雌激素受体调节剂的治疗性组合产品 |
| EP3233828B1 (en) | 2014-12-18 | 2020-03-04 | F. Hoffmann-La Roche AG | Estrogen receptor modulators and uses thereof |
| JP2017538727A (ja) * | 2014-12-18 | 2017-12-28 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 癌の治療に有用な２，３−ジフェニルクロメンの誘導体 |
| EA032311B1 (ru) | 2014-12-18 | 2019-05-31 | Ф. Хоффманн-Ля Рош Аг | Тетрагидро-пиридо[3,4-b]индоловые модуляторы эстрогеновых рецепторов и их применение |
| WO2016189011A1 (en) * | 2015-05-26 | 2016-12-01 | F. Hoffmann-La Roche Ag | Heterocyclic estrogen receptor modulators and uses thereof |
| WO2017024319A1 (en) | 2015-08-06 | 2017-02-09 | Dana-Farber Cancer Institute, Inc. | Tunable endogenous protein degradation |
| HUE055321T2 (hu) | 2015-10-01 | 2021-11-29 | Olema Pharmaceuticals Inc | Tetrahidro-1H-pirido[3,4-b]indol anti-ösztrogén hatóanyagok |
| US10865199B2 (en) * | 2015-10-27 | 2020-12-15 | Sun Pharma Advanced Research Company Limited | Heterocyclic antiestrogens |
| WO2017080338A1 (zh) | 2015-11-12 | 2017-05-18 | 浙江海正药业股份有限公司 | 丙烯酸类衍生物、其制备方法及其在医药上的用途 |
| CA3008020C (en) | 2015-12-09 | 2024-02-20 | The Board Of Trustees Of The University Of Illinois | Benzothiophene-based selective estrogen receptor downregulators |
| ES2842579T3 (es) | 2016-02-05 | 2021-07-14 | Inventisbio Llc | Degradadores de los receptores de estrógenos selectivos y sus usos |
| IL295050A (en) | 2016-04-01 | 2022-09-01 | Recurium Ip Holdings Llc | Estrogen receptor modulators |
| US10125135B2 (en) | 2016-04-20 | 2018-11-13 | Astrazeneca Ab | Chemical compounds |
| ES2989988T3 (es) | 2016-05-10 | 2024-11-28 | C4 Therapeutics Inc | Degronímeros heterorocíclicos para la degradación de proteínas diana |
| CN109641874A (zh) | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
| WO2017197036A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
| CN109790143A (zh) | 2016-05-10 | 2019-05-21 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| US20180002344A1 (en) | 2016-06-16 | 2018-01-04 | Genentech, Inc. | Heteroaryl estrogen receptor modulators and uses thereof |
| CN109789143A (zh) | 2016-07-01 | 2019-05-21 | G1治疗公司 | 基于嘧啶的抗增殖剂 |
| WO2018019793A1 (en) | 2016-07-25 | 2018-02-01 | Astrazeneca Ab | N-(2-(4-((1r,3r)-3-methyl-2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indol-1-yl)phenoxy)ethyl)propan-1-amine derivatives and related compounds as selective down-regulators of the estrogen receptor for treating cancer |
| WO2018081168A2 (en) | 2016-10-24 | 2018-05-03 | The Board Of Trustees Of The University Of Illinois | Benzothiophene-based selective mixed estrogen receptor downregulators |
| JP6744489B2 (ja) | 2016-10-24 | 2020-08-19 | アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ | 癌の治療において有用な６，７，８，９−テトラヒドロ−３Ｈ−ピラゾロ［４，３−ｆ］イソキノリン誘導体 |
| WO2018129419A1 (en) * | 2017-01-05 | 2018-07-12 | Radius Pharmaceuticals, Inc. | Polymorphic forms of rad1901-2hcl |
| MX2019008158A (es) | 2017-01-06 | 2019-12-09 | G1 Therapeutics Inc | Terapia de combinacion para el tratamiento del cancer. |
| JOP20190183B1 (ar) | 2017-01-30 | 2022-09-15 | Astrazeneca Ab | معدِلات مستقبلات الاستروجين |
| EP4119552A1 (en) | 2017-02-08 | 2023-01-18 | Dana-Farber Cancer Institute, Inc. | Regulating chimeric antigen receptors |
| US10208011B2 (en) | 2017-02-10 | 2019-02-19 | G1 Therapeutics, Inc. | Benzothiophene estrogen receptor modulators |
| CN118440096A (zh) | 2017-06-20 | 2024-08-06 | C4医药公司 | 用于蛋白降解的n/o-连接的降解决定子和降解决定子体 |
| KR102659211B1 (ko) | 2017-06-29 | 2024-04-18 | 쥐원 쎄라퓨틱스, 인크. | G1t38의 형체 형태 및 그의 제조 방법 |
| CN111032627B (zh) * | 2017-09-25 | 2023-10-20 | 罗欣健康科技发展(北京)有限公司 | 一种雌激素受体抑制剂的晶型及其制备方法 |
| US11624095B2 (en) | 2017-09-27 | 2023-04-11 | Case Western Reserve University | Method of quantifying HIV reservoirs by induced transcription based sequencing |
| CA3079407A1 (en) | 2017-10-18 | 2019-04-25 | Novartis Ag | Compositions and methods for selective protein degradation |
| CA3081602A1 (en) | 2017-11-16 | 2019-05-23 | Novartis Ag | Combination therapies |
| CN111902141A (zh) | 2018-03-26 | 2020-11-06 | C4医药公司 | 用于ikaros降解的羟脑苷脂结合剂 |
| CN118239948A (zh) | 2018-06-21 | 2024-06-25 | 豪夫迈·罗氏有限公司 | 固体形式及制备稠合三环化合物的方法，包括其使用方法 |
| SG11202013177WA (en) | 2018-07-04 | 2021-01-28 | Radius Pharmaceuticals Inc | Polymorphic forms of rad 1901-2hcl |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| CN108911967A (zh) * | 2018-08-03 | 2018-11-30 | 上海华堇生物技术有限责任公司 | 2,5–二甲氧基苯甲酰氯的制备方法 |
| MX2021001857A (es) | 2018-08-17 | 2021-10-13 | Genentech Inc Star | Metodos de diagnostico y terapeuticos para el tratamiento del cancer de mama. |
| EP3846800A4 (en) | 2018-09-04 | 2022-08-24 | C4 Therapeutics, Inc. | Compounds for the degradation of brd9 or mth1 |
| CN113453679B (zh) | 2018-12-20 | 2025-07-08 | C4医药公司 | 靶向蛋白降解 |
| EP3897637A1 (en) | 2018-12-20 | 2021-10-27 | Novartis AG | Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
| CN113348163B (zh) | 2019-02-12 | 2024-10-08 | 雷迪厄斯制药公司 | 方法和化合物 |
| EP3924054B1 (en) | 2019-02-15 | 2025-04-02 | Novartis AG | 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| CA3123519A1 (en) | 2019-02-15 | 2020-08-20 | Novartis Ag | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| CA3252762A1 (en) | 2019-04-12 | 2025-07-08 | C4 Therapeutics, Inc. | Tricyclic degraders of ikaros and aiolos |
| WO2020219742A1 (en) | 2019-04-24 | 2020-10-29 | Novartis Ag | Compositions and methods for selective protein degradation |
| TW202100184A (zh) | 2019-05-20 | 2021-01-01 | 瑞士商諾華公司 | Mcl-1抑制劑抗體－藥物結合物及使用方法 |
| WO2020238733A1 (zh) | 2019-05-24 | 2020-12-03 | 浙江海正药业股份有限公司 | 丙烯酸类衍生物的晶型及其制备方法和用途 |
| CA3144791A1 (en) | 2019-07-07 | 2021-01-14 | Olema Pharmaceuticals, Inc. | Regimens of estrogen receptor antagonists |
| US11014915B2 (en) | 2019-07-22 | 2021-05-25 | Sun Pharma Advanced Research Company Limited | Selective estrogen receptor degrader |
| CN114269342A (zh) | 2019-08-06 | 2022-04-01 | 里科瑞尔姆Ip控股有限责任公司 | 用于治疗突变的雌激素受体调节剂 |
| BR112022011998A2 (pt) | 2019-12-20 | 2022-08-30 | Novartis Ag | Usos de anticorpos anti-tgfss e inibidores de checkpoint para o tratamento de doenças proliferativas |
| EP4681715A2 (en) | 2019-12-20 | 2026-01-21 | C4 Therapeutics, Inc. | Isoindolinone and indazole compounds for the degradation of egfr |
| AU2021231898A1 (en) | 2020-03-05 | 2022-10-27 | C4 Therapeutics, Inc. | Compounds for targeted degradation of BRD9 |
| AU2021260829B2 (en) | 2020-04-24 | 2024-01-11 | Astrazeneca Ab | Dosage regimen for the treatment of cancer |
| KR20230005270A (ko) | 2020-04-24 | 2023-01-09 | 아스트라제네카 아베 | 약학적 제형 |
| EP4652997A2 (en) | 2020-05-19 | 2025-11-26 | Pharmacosmos Holding A/s | Cyclin-dependent kinase inhibiting compounds for the treatment of medical disorders |
| EP4168007A1 (en) | 2020-06-23 | 2023-04-26 | Novartis AG | Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
| EP4188549A1 (en) | 2020-08-03 | 2023-06-07 | Novartis AG | Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| EP4192458A4 (en) | 2020-08-05 | 2024-09-04 | C4 Therapeutics, Inc. | COMPOUNDS FOR TARGETED DEGRADATION OF RET |
| US20250171423A1 (en) | 2020-09-23 | 2025-05-29 | Achillion Pharmaceuticals, Inc. | Pharmaceutical compounds for the treatment of complement mediated disorders |
| KR20230138444A (ko) | 2020-11-24 | 2023-10-05 | 노파르티스 아게 | Mcl-1 억제제 항체-약물 접합체 및 사용 방법 |
| WO2022112942A2 (en) | 2020-11-24 | 2022-06-02 | Novartis Ag | Anti-cd48 antibodies, antibody drug conjugates, and uses thereof |
| EP4267578A4 (en) | 2020-12-23 | 2024-11-20 | Recurium IP Holdings, LLC | ESTROGEN RECEPTOR MODULATORS |
| IL304891A (en) | 2021-02-02 | 2023-10-01 | Servier Lab | Selective Protech BCL-XL compounds and methods of use |
| CN115073273B (zh) * | 2021-03-15 | 2024-09-17 | 中国医学科学院药物研究所 | 二苯烷类化合物及其制备方法、药物组合物和用途 |
| TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途 |
| AR125874A1 (es) | 2021-05-18 | 2023-08-23 | Novartis Ag | Terapias de combinación |
| CN117940133A (zh) | 2021-06-08 | 2024-04-26 | C4医药公司 | 用于突变braf的降解的治疗剂 |
| CA3256012A1 (en) | 2022-05-20 | 2023-11-23 | Les Laboratoires Servier | ANTIBODY-DRUG CONJUGATES, MET INHIBITORS BCL-XL, AND THEIR METHODS OF USE |
| WO2023225320A1 (en) | 2022-05-20 | 2023-11-23 | Novartis Ag | Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof |
| EP4565585A1 (en) | 2022-08-03 | 2025-06-11 | Bristol-Myers Squibb Company | Compounds for modulating ret protein |
| WO2024097989A1 (en) | 2022-11-04 | 2024-05-10 | Bristol-Myers Squibb Company | Ret-ldd protein degraders |
| EP4611900A1 (en) | 2022-11-04 | 2025-09-10 | Bristol-Myers Squibb Company | Ret-ldd protein inhibitors |
| AU2024234194A1 (en) | 2023-03-10 | 2025-08-07 | Novartis Ag | Panras inhibitor antibody-drug conjugates and methods of use thereof |
| WO2025006753A2 (en) | 2023-06-30 | 2025-01-02 | Merck Patent Gmbh | Heterobifunctional compounds for the degradation of kras protein |
| TW202540185A (zh) | 2023-11-22 | 2025-10-16 | 法商施維雅藥廠 | 抗cd74抗體藥物結合物及其使用方法 |
| WO2025215536A1 (en) | 2024-04-10 | 2025-10-16 | Novartis Ag | Macrocyclic panras inhibitors for the treatment of cancer |
Family Cites Families (118)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4229447A (en) | 1979-06-04 | 1980-10-21 | American Home Products Corporation | Intraoral methods of using benzodiazepines |
| US4596795A (en) | 1984-04-25 | 1986-06-24 | The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services | Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives |
| EP0230654B1 (en) | 1985-12-28 | 1992-03-18 | Sumitomo Pharmaceuticals Company, Limited | Sustained pulsewise release pharmaceutical preparation |
| US4755386A (en) | 1986-01-22 | 1988-07-05 | Schering Corporation | Buccal formulation |
| US5395842A (en) | 1988-10-31 | 1995-03-07 | Endorecherche Inc. | Anti-estrogenic compounds and compositions |
| US5686465A (en) | 1988-10-31 | 1997-11-11 | Endorecherche Inc. | Sex steroid activity inhibitors |
| US5739136A (en) | 1989-10-17 | 1998-04-14 | Ellinwood, Jr.; Everett H. | Intraoral dosing method of administering medicaments |
| US5017381A (en) | 1990-05-02 | 1991-05-21 | Alza Corporation | Multi-unit pulsatile delivery system |
| EP0470310B1 (en) * | 1990-08-09 | 1995-11-29 | Council of Scientific and Industrial Research | Novel benzopyrans and process for their production |
| US5254568A (en) | 1990-08-09 | 1993-10-19 | Council Of Scientific & Industrial Research | Benzopyrans as antiestrogenic agents |
| US5229135A (en) | 1991-11-22 | 1993-07-20 | Prographarm Laboratories | Sustained release diltiazem formulation |
| US6060503A (en) | 1991-12-02 | 2000-05-09 | Endorecherche, Inc. | Benzopyran-containing compounds and method for their use |
| ATE157869T1 (de) | 1993-06-24 | 1997-09-15 | Lilly Co Eli | Antiöstrogene 2-phenyl-3-aroylbenzothiophene als hypoglykämische mittel |
| US5407947A (en) * | 1993-11-05 | 1995-04-18 | Eli Lilly And Company | Methods for inhibiting bone loss using pyrolidine and piperidine substituted benzopyrans |
| US5446061A (en) | 1993-11-05 | 1995-08-29 | Eli Lilly And Company | Methods for lowering serum cholesterol |
| US5416098A (en) | 1993-12-30 | 1995-05-16 | Zymogenetics, Inc. | Method for treating dermatitis and related conditions |
| US5389646A (en) | 1993-12-30 | 1995-02-14 | Zymogenetics, Inc. | Methods for treatment and prevention of bone loss using 2,3-benzopyrans |
| US5681835A (en) | 1994-04-25 | 1997-10-28 | Glaxo Wellcome Inc. | Non-steroidal ligands for the estrogen receptor |
| TW398975B (en) | 1994-07-22 | 2000-07-21 | Lilly Co Eli | Pharmaceutical composition for inhibiting bone loss |
| US5637598A (en) | 1994-11-18 | 1997-06-10 | Eli Lilly And Company | Methods of inhibiting bone loss |
| US5446071A (en) | 1994-11-18 | 1995-08-29 | Eli Lilly And Company | Methods for lowering serum cholesterol |
| US5837284A (en) | 1995-12-04 | 1998-11-17 | Mehta; Atul M. | Delivery of multiple doses of medications |
| US5980938A (en) | 1996-07-15 | 1999-11-09 | Eli Lilly And Company | Effect of compounds that suppress induction of plasminogen activator inhibitor 1 (PAI-1) |
| EP0937060B1 (en) | 1996-10-28 | 2002-12-11 | Novo Nordisk A/S | Cis-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes |
| US5840329A (en) | 1997-05-15 | 1998-11-24 | Bioadvances Llc | Pulsatile drug delivery system |
| AU8102398A (en) | 1997-07-09 | 1999-02-08 | Central Drug Research Institute | (dl)-2,3-diaryl-2h-1-benzopyrans |
| AU8102498A (en) | 1997-07-09 | 1999-02-08 | Central Drug Research Institute | Preparation of diaryl-benzopyrans |
| KR20010022956A (ko) | 1997-08-15 | 2001-03-26 | 듀크 유니버시티 | 에스트로겐-의존성 질병 및 장애의 예방방법 또는 치료방법 |
| ID24568A (id) | 1997-11-06 | 2000-07-27 | American Home Prod | Kontrasepsi oral yang mengandung anti-estrogen plus progestin |
| US6326392B1 (en) | 1997-11-06 | 2001-12-04 | American Home Products Corporation | Anti-estrogen plus progestin containing oral contraceptives |
| WO1999060014A2 (en) | 1998-03-30 | 1999-11-25 | The Regents Of The University Of California | Methods and compounds for modulating nuclear receptor coactivator binding |
| AU3457199A (en) | 1998-03-30 | 1999-10-18 | Arch Development Corporation | Methods and compounds for modulating nuclear receptor activity |
| US6465445B1 (en) * | 1998-06-11 | 2002-10-15 | Endorecherche, Inc. | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
| US7005428B1 (en) | 1998-06-11 | 2006-02-28 | Endorecherche, Inc. | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
| US6262270B1 (en) * | 1998-08-14 | 2001-07-17 | Schering Corporation | Enantioselective synthesis |
| WO2000009493A1 (en) | 1998-08-14 | 2000-02-24 | Schering Corporation | Enantioselective synthesis |
| WO2000037083A1 (en) | 1998-12-18 | 2000-06-29 | Schering Corporation | Oral antiestrogen pharmaceutical composition |
| US6638727B1 (en) | 1999-01-26 | 2003-10-28 | Cytyc Health Corporation | Methods for identifying treating or monitoring asymptomatic patients for risk reduction or therapeutic treatment of breast cancer |
| US6716452B1 (en) | 2000-08-22 | 2004-04-06 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
| DE19916419B4 (de) | 1999-04-08 | 2005-06-16 | Schering Ag | Kombinationspräparat aus Vitamin-D-Metaboliten oder Vitamin-D-Analoga und einem Östrogenpartialagonisten zur Behandlung von Osteoporose |
| BR0012354A (pt) | 1999-07-06 | 2002-04-02 | Endorech Inc | Compostos e composição farmacêutica e métodos para tratar e/ou suprimir ganho de peso |
| WO2001026651A2 (en) | 1999-10-14 | 2001-04-19 | Endorecherche, Inc. | Selective estrogen receptor modulators in the treatment or reduction of the risk of acquiring hypertension, cardiovascular diseases, and insulin resistance |
| GB0000313D0 (en) | 2000-01-10 | 2000-03-01 | Astrazeneca Uk Ltd | Formulation |
| CO5271709A1 (es) | 2000-01-12 | 2003-04-30 | Pfizer Prod Inc | Composiciones y procedimientos para el y tratamiento de afecciones que responden a estrogenos |
| CO5271696A1 (es) | 2000-01-12 | 2003-04-30 | Pfizer Prod Inc | Procedimiento para reducir la morbilidad y el riesgo de mortalidad |
| CO5271697A1 (es) | 2000-01-12 | 2003-04-30 | Pfizer Prod Inc | Composiciones y procedimientos para el tratamiento de afecciones que responden a un aumento de testosterona |
| CO5251465A1 (es) | 2000-01-26 | 2003-02-28 | Pfizer Prod Inc | Composiciones y procedimientos para tratar la osteoporosis y reducir el colesterol |
| IL149990A0 (en) | 2000-01-28 | 2002-12-01 | Endorech Inc | Selective estrogen receptor modulators in combination with estrogens |
| AU2001238700A1 (en) | 2000-02-22 | 2001-09-03 | Board Of Regents, The University Of Texas System | Compositions and methods of use of het, a novel modulator of estrogen action |
| DE10013782A1 (de) * | 2000-03-15 | 2001-10-18 | Schering Ag | 4-Fluoralkyl-2H-benzopyrane mit antiestrogener Wirksamkeit, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln |
| US6528681B2 (en) | 2000-04-05 | 2003-03-04 | Bristol-Meyers Squibb Pharma Company | Halogenated triphenylethylene derivatives as selective estrogen receptor modulators |
| US20020013327A1 (en) | 2000-04-18 | 2002-01-31 | Lee Andrew G. | Compositions and methods for treating female sexual dysfunction |
| US7863011B2 (en) | 2000-05-10 | 2011-01-04 | Signe Biopharma, Inc. | Screening method for predicting susceptibility to breast cancer |
| US8119138B2 (en) | 2000-05-10 | 2012-02-21 | Signe Biopharma Inc. | Anti-estrogen and immune modulator combinations for treating breast cancer |
| EP1177787A3 (en) | 2000-07-28 | 2003-09-10 | Pfizer Products Inc. | Use of an estrogen agonist/antagonist for treating cataracts |
| ATE278421T1 (de) | 2000-08-11 | 2004-10-15 | Wyeth Corp | Verfahren zur behandlung eines östrogenrezeptor positives karzinoms |
| US20020099013A1 (en) | 2000-11-14 | 2002-07-25 | Thomas Piccariello | Active agent delivery systems and methods for protecting and administering active agents |
| AU2001289865B2 (en) | 2000-09-08 | 2007-03-01 | Pharmacia Italia S.P.A. | Exemestane as chemopreventing agent |
| EP1192945A3 (en) | 2000-09-21 | 2004-03-03 | Pfizer Products Inc. | Use of an estrogen agonist/antagonist for treating osteoarthritis |
| CA2424299A1 (en) | 2000-10-06 | 2002-04-18 | Biomedicines, Inc. | Combination therapy for the treatment of estrogen-sensitive disease |
| IL145838A (en) | 2000-10-16 | 2008-11-03 | Pfizer Prod Inc | Use of an estrogen agonist/antagonist for the manufacture of a medicament for treating vaginitis |
| EP1328522A2 (en) | 2000-10-19 | 2003-07-23 | Merck & Co., Inc. | Estrogen receptor modulators |
| EP1333827A2 (en) | 2000-10-19 | 2003-08-13 | Merck & Co., Inc. | Estrogen receptor modulators |
| US6750213B2 (en) | 2000-10-19 | 2004-06-15 | Merck & Co., Inc. | Estrogen receptor modulators |
| AU781168B2 (en) | 2001-01-26 | 2005-05-12 | Pfizer Products Inc. | Method of treating certain cancers using an estrogen agonist/antagonist |
| ATE337787T1 (de) | 2001-01-26 | 2006-09-15 | Pfizer Italia Srl | Exemestan zur behandlung von hormonabhängigen störungen |
| US20040082557A1 (en) | 2001-01-26 | 2004-04-29 | Wajszczuk Charles Paul | Methods for treating estrogen-dependent disorders |
| GB2374412A (en) | 2001-04-11 | 2002-10-16 | Karobio Ab | Hypertension treatment and assay |
| WO2003016270A2 (en) | 2001-08-11 | 2003-02-27 | Bristol-Myers Squibb Pharma Company | Selective estrogen receptor modulators |
| WO2003026568A2 (en) | 2001-09-21 | 2003-04-03 | Merck & Co., Inc. | Androstanes as androgen receptor modulators |
| AU2002331916B2 (en) | 2001-10-03 | 2008-07-24 | Merck Sharp & Dohme Corp. | Androstane 17-beta-carboxamides as androgen receptor modulators |
| CA2463142A1 (en) | 2001-10-10 | 2003-04-24 | Pharmacia Italia Spa | Methods for preventing and treating bone loss with steroid compounds |
| US7196076B2 (en) | 2001-10-19 | 2007-03-27 | Merck & Co., Inc. | Androgen receptor modulators and methods of use thereof |
| US7105679B2 (en) * | 2001-12-19 | 2006-09-12 | Kanojia Ramesh M | Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators |
| IL162295A0 (en) * | 2001-12-19 | 2005-11-20 | Ortho Mcneil Pharm Inc | Tetracyclic heterocompounds as estrogen receptor modulators |
| EP1465619A1 (en) | 2002-01-14 | 2004-10-13 | Nordic Bioscience A/S | Suppression of cartilage degradation via the estrogen receptor |
| AU2003206442A1 (en) | 2002-02-21 | 2003-09-09 | Pantarhei Bioscience B.V. | Estrogenic component for treating decreased libido in women |
| CN1625602A (zh) | 2002-03-13 | 2005-06-08 | 霍夫曼-拉罗奇有限公司 | 选择药物敏感性决定因子的方法和利用所选择的因子预测药物敏感性的方法 |
| AU2003218235B2 (en) | 2002-03-13 | 2008-05-15 | Merck Sharp & Dohme Corp. | Fluorinated 4-azasteroid derivatives as androgen receptor modulators |
| US20030225132A1 (en) | 2002-04-11 | 2003-12-04 | Dininno Frank P. | Estrogen receptor modulators |
| DK1501819T3 (da) * | 2002-04-24 | 2011-01-10 | Merck Sharp & Dohme | Østrogenreceptormodulatorer |
| AU2003223754B2 (en) | 2002-04-30 | 2007-08-16 | Merck Sharp & Dohme Corp. | 4-azasteroid derivatives as androgen receptor modulators |
| WO2004000225A2 (en) | 2002-06-25 | 2003-12-31 | Wyeth | Use of thio-oxindole derivatives in treatment of hormone-related conditions |
| KR20050013247A (ko) | 2002-06-25 | 2005-02-03 | 와이어쓰 | 호르몬-관련 병리상태를 치료하기 위한사이클로티오카바메이트 유도체의 용도 |
| US7622592B2 (en) | 2002-11-01 | 2009-11-24 | Merck & Co., Inc. | Carbonylamino-benzimidazole derivatives as androgen receptor modulators |
| WO2004091488A2 (en) * | 2003-04-14 | 2004-10-28 | Merck & Co., Inc. | Estrogen receptor modulators |
| DK1622630T3 (da) | 2003-05-07 | 2012-12-17 | Osteologix As | P009368epdk1 |
| AU2004238238C1 (en) | 2003-05-07 | 2010-01-14 | Merck Sharp & Dohme Corp. | Androgen receptor modulators and methods of use thereof |
| US20040248989A1 (en) | 2003-06-05 | 2004-12-09 | Risto Santti | Method for the treatment or prevention of lower urinary tract symptoms |
| CN1812824A (zh) | 2003-06-30 | 2006-08-02 | 麦克公司 | 作为雄激素受体调节剂的17－乙酰氨基－4－氮杂甾体衍生物 |
| CN1816370A (zh) | 2003-06-30 | 2006-08-09 | 麦克公司 | 用作雄激素受体调节剂的17－乙酰氨基－4－氮杂甾族化合物衍生物 |
| US20070088028A1 (en) | 2003-06-30 | 2007-04-19 | Dankulich William P | 17-Acetamido-4-azasteroid derivatives as androgen receptor modulators |
| CA2530047A1 (en) | 2003-06-30 | 2005-02-03 | Merck & Co., Inc. | 17-acetamido-4-azasteroid derivatives as androgen receptor modulators |
| CA2537663A1 (en) | 2003-09-10 | 2005-03-24 | Merck & Co., Inc. | 17-heterocyclic-4-azasteroid derivatives as androgen receptor modulators |
| AU2004272007B2 (en) | 2003-09-10 | 2009-05-28 | Merck Sharp & Dohme Corp. | 17-heterocyclic-4-azasteroid derivatives as androgen receptor modulators |
| US7442833B2 (en) | 2003-10-08 | 2008-10-28 | Smithkline Beecham Corporation | Triphenylethylene compounds as selective estrogen receptor modulators |
| US7312229B2 (en) | 2003-10-31 | 2007-12-25 | Merck & Co., Inc. | 21-Heterocyclic-4-azasteroid derivatives as androgen receptor modulators |
| WO2005073190A1 (en) | 2004-01-29 | 2005-08-11 | Eli Lilly And Company | Selective estrogen receptor modulators |
| UA87854C2 (en) | 2004-06-07 | 2009-08-25 | Мерк Энд Ко., Инк. | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators |
| EP1758653A2 (en) | 2004-06-17 | 2007-03-07 | Osteologix A/S | Treatments comprising strontium for rheumatic and arthritic diseases and pain |
| WO2005123130A2 (en) | 2004-06-17 | 2005-12-29 | Osteologix A/S | Improved treatments of rheumatic and arthritic diseases comprising combinations of a 5-lipoxygenase inhibitor |
| KR20070059110A (ko) | 2004-09-03 | 2007-06-11 | 호르모스 메디칼 리미티드 | 안드로겐 결핍의 치료 또는 예방에 사용하는 제제의 제조를위한 선택적 에스트로겐 수용체 조절자의 용도 |
| SG155258A1 (en) | 2004-10-20 | 2009-09-30 | Endorech Inc | Sex steroid precursors alone or in combination with a selective estrogen receptor modulator and/or with estrogens and/or a type 5 cgmp phosphodiesterase inhibitor for the prevention and treatment of vaginal dryness and sexual dysfunction in postmenopausa |
| WO2006084937A1 (en) | 2005-02-14 | 2006-08-17 | Leskelae Hannu-Ville | Method for diagnosing and treating women with increased response to hormonal replacement therapy |
| US20070078114A1 (en) | 2005-09-02 | 2007-04-05 | Myriad Genetics, Incorporated | Combination therapy for alzheimer's disease and other diseases |
| WO2007098090A2 (en) | 2006-02-17 | 2007-08-30 | Novacea, Inc. | Treatment of hyperproliferative diseases with n-oxides of estrogen receptor modulators |
| US20080268041A1 (en) | 2007-04-23 | 2008-10-30 | Jens Hoffmann | Combination of progesterone-receptor antagonist together with none-steroidal antiestrogen for use in brca mediated diseases |
| DE102007026877A1 (de) | 2007-06-08 | 2008-12-11 | Bayer Schering Pharma Aktiengesellschaft | Verwendung des Fibroblastenwachstumsfaktors 7 (Fgf7) und des Rezeptors Fgfr2b als Biomarker |
| WO2009143309A2 (en) | 2008-05-21 | 2009-11-26 | Trustees Of Dartmouth College | Female reproductive tract and anal prophylaxes |
| WO2010107474A1 (en) | 2009-03-16 | 2010-09-23 | The Research Foundation Of State University Of New York | Antiestrogens for breast cancer therapy |
| US20100317635A1 (en) | 2009-06-16 | 2010-12-16 | Endorecherche, Inc. | Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators |
| HRP20170786T1 (hr) * | 2010-06-10 | 2017-08-11 | Seragon Pharmaceuticals, Inc. | Modulatori estrogenskog receptora i njihove uporabe |
| US8853423B2 (en) | 2010-06-17 | 2014-10-07 | Seragon Pharmaceuticals, Inc. | Indane estrogen receptor modulators and uses thereof |
| DE102010030538A1 (de) | 2010-06-25 | 2011-12-29 | Bayer Schering Pharma Aktiengesellschaft | 6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln |
| GB2483736B (en) * | 2010-09-16 | 2012-08-29 | Aragon Pharmaceuticals Inc | Estrogen receptor modulators and uses thereof |
| JP5886873B2 (ja) | 2010-12-24 | 2016-03-16 | メルク・シャープ・エンド・ドーム・ベー・フェー | Ｎ置換アゼチジン誘導体 |
| MX357496B (es) | 2011-12-14 | 2018-07-11 | Seragon Pharmaceuticals Inc | Moduladores del receptor de estrógenos fluorados y sus usos. |
| AU2012353660A1 (en) | 2011-12-16 | 2014-06-12 | Olema Pharmaceuticals, Inc. | Novel benzopyran compounds, compositions and uses thereof |
-
2011
- 2011-06-08 HR HRP20170786TT patent/HRP20170786T1/hr unknown
- 2011-06-08 SG SG2012084737A patent/SG185637A1/en unknown
- 2011-06-08 DK DK11793115.4T patent/DK2580210T5/en active
- 2011-06-08 PL PL11793115T patent/PL2580210T3/pl unknown
- 2011-06-08 LT LTEP11793115.4T patent/LT2580210T/lt unknown
- 2011-06-08 EA EA201270815A patent/EA022551B1/ru not_active IP Right Cessation
- 2011-06-08 CA CA2800673A patent/CA2800673A1/en not_active Abandoned
- 2011-06-08 US US13/702,394 patent/US8703810B2/en active Active
- 2011-06-08 PH PH1/2012/502419A patent/PH12012502419A1/en unknown
- 2011-06-08 KR KR1020137000592A patent/KR101698238B1/ko not_active Expired - Fee Related
- 2011-06-08 ES ES11793115.4T patent/ES2627692T3/es active Active
- 2011-06-08 EP EP11793115.4A patent/EP2580210B1/en active Active
- 2011-06-08 HU HUE11793115A patent/HUE033581T2/hu unknown
- 2011-06-08 EP EP17157571.5A patent/EP3205648A1/en not_active Withdrawn
- 2011-06-08 RS RS20170530A patent/RS56042B1/sr unknown
- 2011-06-08 BR BR112012031464-5A patent/BR112012031464A2/pt not_active IP Right Cessation
- 2011-06-08 WO PCT/US2011/039669 patent/WO2011156518A2/en not_active Ceased
- 2011-06-08 PT PT117931154T patent/PT2580210T/pt unknown
- 2011-06-08 JP JP2013514346A patent/JP2013528223A/ja active Pending
- 2011-06-08 CN CN201180028527.XA patent/CN102939287B/zh active Active
- 2011-06-08 AU AU2011264858A patent/AU2011264858B2/en not_active Ceased
- 2011-06-08 SI SI201131201T patent/SI2580210T1/sl unknown
- 2011-06-08 MX MX2012014431A patent/MX2012014431A/es active IP Right Grant
-
2012
- 2012-11-15 IL IL223044A patent/IL223044B/en active IP Right Grant
- 2012-11-15 ZA ZA2012/08603A patent/ZA201208603B/en unknown
-
2013
- 2013-12-20 US US14/137,394 patent/US9078871B2/en active Active
-
2016
- 2016-07-28 JP JP2016149008A patent/JP6465840B2/ja active Active
-
2017
- 2017-05-31 CY CY20171100559T patent/CY1120450T1/el unknown
-
2018
- 2018-08-15 JP JP2018153006A patent/JP2018203751A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013528223A5 (enExample) | ||
| JP2019034943A5 (enExample) | ||
| JP2010523476A5 (enExample) | ||
| JP2014523901A5 (enExample) | ||
| JP2004502670A5 (enExample) | ||
| JP2007508360A5 (enExample) | ||
| CN113365997A (zh) | 作为c-Met抑制剂的含嘧啶基团的三并环类化合物 | |
| NZ601408A (en) | Novel 3-hydroxy-5-arylisothiazole derivative | |
| JP2013521291A5 (enExample) | ||
| JP2011523647A5 (enExample) | ||
| JP2007523155A5 (enExample) | ||
| JP2014015465A5 (enExample) | ||
| JP2010500293A5 (enExample) | ||
| JP2009524691A5 (enExample) | ||
| JPWO2020123827A5 (enExample) | ||
| JP2002513793A5 (enExample) | ||
| CN112888687A (zh) | 三氟甲基取代的磺酰胺类选择性bcl-2抑制剂 | |
| JP2017509694A5 (enExample) | ||
| JP2008510778A5 (enExample) | ||
| JP2020534264A5 (enExample) | ||
| JP2008512408A5 (enExample) | ||
| JP2015508092A5 (enExample) | ||
| RU2013130879A (ru) | Производные оксазолилметилового эфира в качестве агонистов рецептора alx | |
| JP2014501789A5 (enExample) | ||
| JP2010506919A5 (enExample) |